SG Americas Securities LLC Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

SG Americas Securities LLC raised its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 39.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,341 shares of the company's stock after purchasing an additional 8,240 shares during the quarter. SG Americas Securities LLC's holdings in CRISPR Therapeutics were worth $998,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Avanza Fonder AB acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth $866,000. Farther Finance Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 46.7% during the first quarter. Farther Finance Advisors LLC now owns 5,626 shares of the company's stock worth $186,000 after buying an additional 1,792 shares in the last quarter. NBC Securities Inc. lifted its holdings in shares of CRISPR Therapeutics by 156,300.0% during the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock worth $53,000 after buying an additional 1,563 shares in the last quarter. Green Alpha Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 132.9% during the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock worth $1,952,000 after buying an additional 32,732 shares in the last quarter. Finally, 180 Wealth Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 22.9% during the first quarter. 180 Wealth Advisors LLC now owns 6,349 shares of the company's stock worth $216,000 after buying an additional 1,182 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRSP. Needham & Company LLC reissued a "buy" rating and set a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Barclays decreased their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. The Goldman Sachs Group decreased their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Finally, Chardan Capital decreased their price objective on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $69.53.

CRISPR Therapeutics Trading Down 0.4%

Shares of CRSP stock traded down $0.18 on Friday, hitting $44.25. 3,052,058 shares of the stock were exchanged, compared to its average volume of 1,781,169. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $63.68. The firm's 50 day moving average is $38.61 and its two-hundred day moving average is $40.60. The firm has a market capitalization of $3.82 billion, a PE ratio of -9.79 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The business's revenue for the quarter was up 71.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.43) EPS. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider now directly owns 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.30% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.